Wachovia Comments on Mylan (MYL) After TEVA/BRL Merger
More News related to BRL
- Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
- Teva and Barr Receive FTC Request for Additional Information
- Teva and Barr Receive FTC Request for Additional Information
- Mylan (MYL) Subsidiary Announces Favorable Court Ruling Against Barr Labs (BRL)
- Barr Labs (BRL) Receives Final FDA Approval for Generic Version of Razadyne(R) Tablets
More News related to MYL
- Mylan (MYL) Subsidiary Announces Favorable Court Ruling Against Barr Labs (BRL)
- Mylan (MYL) Subsidiary, Alphapharm, Wins Patent Challenge on First-to-fFile Opportunity Razadyne(R) Tablets
- Mylan's Alphapharm Victorious in Patent Challenge on First-to-File Opportunity Razadyne(R) Tablets
- Loeb's Third Point Buys Into Starwood (HOT) and Tibco (TIBX), Dumps Yahoo! (YHOO)
- Mylan Named Manufacturer of the Year by AmerisourceBergen Corporation
More News related to TEVA
- Teva (TEVA) and Barr (BRL) Receive FTC Second Request Regarding Pending Acqusition
- Teva and Barr Receive FTC Request for Additional Information
- Teva and Barr Receive FTC Request for Additional Information
- Analyst Reports for Electronic Arts Inc., Teva Pharmaceutical Industries Limited, ACADIA Pharmaceuticals Inc., and Sport Supply Group Inc.
- Group Acquires IVAX Diagnostics (IVD) Shares From Teva Pharmaceutical (TEVA) for $14 Million
More News related to Analyst Comments
- Apple (AAPL) Event Could Be Disappointment -AmTech
- Goldman Sachs Removed EOG Resources (EOG) from its Conviction Buy List
- Goldman Sachs Removed ConocoPhillips (COP) from its Conviction Buy List
- Goldman Sachs added Devon Energy (DVN) to Conviction Buy List
- Goldman Sachs Added Quest Software (QSFT) to their Conviction Buy List
Wachovia thinks Teva Phama's (Nasdaq: TEVA) buyout of Barr (NYSE: BRL) could spin Mylan (NYSE: MYL) into action.
The firm said, "With TEVA springing ahead of MYL as a result of the BRL transaction, we wonder if this could prompt MYL into looking at near-term acquisition opportunities (the same can be said of Sandoz, a Novartis subsidiary). While it is certainly possible that MYL could entertain a near-term acquisition, the ongoing integration of Merck Generics could present a challenge for MYL management to execute two simultaneous integrations."
Related Categories
Analyst CommentsRumors
Stocks Mentioned
-0.14Related Entities
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
